Its loss of function causes similar symptoms as parkinsonism-dystonia with neurodegeneration and hypermanganesemia in childhood (Table 2) [52], indicating that although ZIP14 may be a therapeutic target, further investigations to clarify the molecular basis of ZIP14 are needed, as described below. This evidence concerns the gene SLC39A14 and Dystonia.